{"entity":{"type":"insider","cik":"0001470741","url":"/insider/0001470741","json_url":"/insider/0001470741.json","name":"LICHTINGER PEDRO","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":9,"n_filings":8,"first":"2011-08-04","last":"2017-03-14","span_basis":"filed_date"},"name_variants":[{"name":"LICHTINGER PEDRO","source":"filing","n_filings":8,"first_seen":"2011-08-04","last_seen":"2017-03-14"}],"transactions":[{"id":4980160,"accession":"0001596771-17-000022","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001596771-17-000022","line_url":"/filing/0001596771-17-000022#line-1","is_derivative":false,"issuer_cik":"0001470741","issuer_name":"Gemphire Therapeutics Inc.","issuer_ticker":"GEMP","issuer_name_source":null,"issuer_url":"/issuer/0001470741","owner_cik":"0001470741","owner_name":"LICHTINGER PEDRO","owner_display_name":"LICHTINGER PEDRO","owner_url":"/insider/0001470741","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10559.0,"shares_display":"10,559","price_per_share":9.47,"price_display":"9.47","price_state":"stated","total_value":99993.73,"total_display":"99,993.73","total_whole":"99,994","shares_owned_after":59833.0,"shares_owned_after_display":"59,833","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-03-10","filed_date":"2017-03-14","scope":"insider"},{"id":2650618,"accession":"0001104659-16-139279","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-16-139279","line_url":"/filing/0001104659-16-139279#line-2","is_derivative":false,"issuer_cik":"0001470741","issuer_name":"Gemphire Therapeutics Inc.","issuer_ticker":"GEMP","issuer_name_source":null,"issuer_url":"/issuer/0001470741","owner_cik":"0001470741","owner_name":"LICHTINGER PEDRO","owner_display_name":"LICHTINGER PEDRO","owner_url":"/insider/0001470741","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":100000.0,"total_display":"100,000.00","total_whole":"100,000","shares_owned_after":49274.0,"shares_owned_after_display":"49,274","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-08-10","filed_date":"2016-08-12","scope":"insider"},{"id":8690519,"accession":"0001209191-15-012278","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-15-012278","line_url":"/filing/0001209191-15-012278#line-1","is_derivative":false,"issuer_cik":"0001470741","issuer_name":"Asterias Biotherapeutics, Inc.","issuer_ticker":"AST","issuer_name_source":null,"issuer_url":"/issuer/0001470741","owner_cik":"0001470741","owner_name":"LICHTINGER PEDRO","owner_display_name":"LICHTINGER PEDRO","owner_url":"/insider/0001470741","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Series A Common Stock, par value $0.0001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":128205.0,"shares_display":"128,205","price_per_share":3.9,"price_display":"3.90","price_state":"stated","total_value":499999.5,"total_display":"499,999.50","total_whole":"500,000","shares_owned_after":528205.0,"shares_owned_after_display":"528,205","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-02-09","filed_date":"2015-02-11","scope":"insider"},{"id":5511083,"accession":"0001209191-13-031061","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-13-031061","line_url":"/filing/0001209191-13-031061#line-1","is_derivative":false,"issuer_cik":"0000876343","issuer_name":"BIOTIME INC","issuer_ticker":"BTX","issuer_name_source":null,"issuer_url":"/issuer/0000876343","owner_cik":"0001470741","owner_name":"LICHTINGER PEDRO","owner_display_name":"LICHTINGER PEDRO","owner_url":"/insider/0001470741","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Shares, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":120000.0,"shares_display":"120,000","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":126250.0,"shares_owned_after_display":"126,250","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-06-04","filed_date":"2013-06-06","scope":"insider"},{"id":4811643,"accession":"0001142576-13-000011","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001142576-13-000011","line_url":"/filing/0001142576-13-000011","is_derivative":false,"issuer_cik":"0001142576","issuer_name":"OPTIMER PHARMACEUTICALS INC","issuer_ticker":"OPTR","issuer_name_source":null,"issuer_url":"/issuer/0001142576","owner_cik":"0001470741","owner_name":"LICHTINGER PEDRO","owner_display_name":"LICHTINGER PEDRO","owner_url":"/insider/0001470741","role":"Other","role_mark":"*","role_mark_label":"Other","role_mark_generic":"Other","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":148000.0,"shares_display":"148,000","price_per_share":14.689128378378378,"price_display":"14.69","price_state":"stated","total_value":2173991.0,"total_display":"2,173,991.00","total_whole":"2,173,991","shares_owned_after":104078.0,"shares_owned_after_display":"104,078","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-04-08","filed_date":"2013-04-10","scope":"insider","n_lines":2},{"id":3550745,"accession":"0001142576-12-000036","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001142576-12-000036","line_url":"/filing/0001142576-12-000036#line-1","is_derivative":false,"issuer_cik":"0001142576","issuer_name":"OPTIMER PHARMACEUTICALS INC","issuer_ticker":"OPTR","issuer_name_source":null,"issuer_url":"/issuer/0001142576","owner_cik":"0001470741","owner_name":"LICHTINGER PEDRO","owner_display_name":"LICHTINGER PEDRO","owner_url":"/insider/0001470741","role":"Officer (CEO and President)","role_mark":"O","role_mark_label":"Officer (CEO and President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":11000.0,"shares_display":"11,000","price_per_share":9.077,"price_display":"9.08","price_state":"stated","total_value":99847.0,"total_display":"99,847.00","total_whole":"99,847","shares_owned_after":104078.0,"shares_owned_after_display":"104,078","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-11-08","filed_date":"2012-11-19","scope":"insider"},{"id":3256461,"accession":"0001209191-12-022856","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-12-022856","line_url":"/filing/0001209191-12-022856#line-1","is_derivative":false,"issuer_cik":"0000876343","issuer_name":"BIOTIME INC","issuer_ticker":"BTX","issuer_name_source":null,"issuer_url":"/issuer/0000876343","owner_cik":"0001470741","owner_name":"LICHTINGER PEDRO","owner_display_name":"LICHTINGER PEDRO","owner_url":"/insider/0001470741","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Shares, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6250.0,"shares_display":"6,250","price_per_share":3.976,"price_display":"3.98","price_state":"stated","total_value":24850.0,"total_display":"24,850.00","total_whole":"24,850","shares_owned_after":6250.0,"shares_owned_after_display":"6,250","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-04-11","filed_date":"2012-04-12","scope":"insider"},{"id":8863999,"accession":"0001142576-11-000028","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001142576-11-000028","line_url":"/filing/0001142576-11-000028#line-1","is_derivative":false,"issuer_cik":"0001142576","issuer_name":"OPTIMER PHARMACEUTICALS INC","issuer_ticker":"OPTR","issuer_name_source":null,"issuer_url":"/issuer/0001142576","owner_cik":"0001470741","owner_name":"LICHTINGER PEDRO","owner_display_name":"LICHTINGER PEDRO","owner_url":"/insider/0001470741","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25000.0,"shares_display":"25,000","price_per_share":8.978,"price_display":"8.98","price_state":"stated","total_value":224450.0,"total_display":"224,450.00","total_whole":"224,450","shares_owned_after":90720.0,"shares_owned_after_display":"90,720","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-08-04","filed_date":"2011-08-04","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":9,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":7,"open_market":true},{"code":"S","label":"Open-market sale","n":2,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":9},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001638287","name":"Gemphire Therapeutics Inc.","url":"/issuer/0001638287","role":"Director","n_filings":2,"first_seen":"2016-08-12","last_seen":"2017-03-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001572552","name":"Asterias Biotherapeutics, Inc.","url":"/issuer/0001572552","role":"Director, Officer (Chief Executive Officer)","n_filings":1,"first_seen":"2015-02-11","last_seen":"2015-02-11"},{"type":"issuer","type_label":"ISSUER","cik":"0000876343","name":"BIOTIME INC","url":"/issuer/0000876343","role":"Director","n_filings":2,"first_seen":"2012-04-12","last_seen":"2013-06-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001142576","name":"OPTIMER PHARMACEUTICALS INC","url":"/issuer/0001142576","role":"Director, Officer (CEO and President), Other","n_filings":3,"first_seen":"2011-08-04","last_seen":"2013-04-10"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001470741","retrieved_at":"2026-08-23T13:01:17+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}